CXCL8 and melanoma: In an additional investigation, Sanmamed et al. [43] demonstrated that in 16 melanoma patients treated with BRAFi monotherapy, serum levels of IL-8 at the time of best response were significantly lower than those detected at baseline and raised again at progression on treatment.